首页期刊导航|癌症生物学与医学（英文版）
期刊信息/Journal information
癌症生物学与医学（英文版）
癌症生物学与医学（英文版）

郝希山

季刊

2095-3941

editor@cancerbiomed.org

022-23522919

300060

天津市河西区体院北环湖西路天津市肿瘤医院C座综合楼三楼

癌症生物学与医学（英文版）/Journal Cancer Biology & MedicineCSCDCSTPCD北大核心SCI
查看更多>>Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:● Cancer epigenetics● Cancer stem cell● Improved in vivo and in vitro cancer models● Cancer prevention and epidemiology● Biomarkers for predicting drug response● Mechanism of drug sensitivity and resistance● New approaches for cancer detection and diagnosis● Oncology clinical trials● Targeted therapy● Multidisciplinary treatment for cancerAuthor benefits: ● Easy online submission via Editorial Manager● Efficient and professional peer-review by expert referees from around the world● Rapid pre-print online publication● No charge for publication and Open Access● International visibility - the journal is available free online
正式出版
收录年代

    Mission of the National Cancer Center Hospital in Japan to promote clinical trials for precision medicine

    Kazuaki ShimadaKenichi NakamuraNoboru Yamamoto
    1-3页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Genomic medicine in clinical practice:national genomic medicine program in Japan

    Yayoi AndoTatsunori ShimoiTatsuya SuzukiHideki Ueno...
    4-9页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Genomic medicine and cancer clinical trial in Thailand

    Lucksamon ThamlikitkulNapa ParinyanitikulVirote Sriuranpong
    10-15页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Current and future trends in whole genome sequencing in cancer

    Yuki Katsuya
    16-20页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Improving the value of molecular testing:current status and opportunities in colorectal cancer precision medicine

    Haiyun LiLinwei GuoChenchen WangXin Hu...
    21-28页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan

    Teruhiko YoshidaYasushi YatabeKen KatoGenichiro Ishii...
    29-44页
    查看更多>>摘要：The journey to implement cancer genomic medicine(CGM)in oncology practice began in the 1980s,which is considered the dawn of genetic and genomic cancer research.At the time,a variety of activating oncogenic alterations and their functional significance were unveiled in cancer cells,which led to the development of molecular targeted therapies in the 2000s and beyond.Although CGM is still a relatively new discipline and it is difficult to predict to what extent CGM will benefit the diverse pool of cancer patients,the National Cancer Center(NCC)of Japan has already contributed considerably to CGM advancement for the conquest of cancer.Looking back at these past achievements of the NCC,we predict that the future of CGM will involve the following:1)A biobank of paired cancerous and non-cancerous tissues and cells from various cancer types and stages will be developed.The quantity and quality of these samples will be compatible with omics analyses.All biobank samples will be linked to longitudinal clinical information.2)New technologies,such as whole-genome sequencing and artificial intelligence,will be introduced and new bioresources for functional and pharmacologic analyses(e.g.,a patient-derived xenograft library)will be systematically deployed.3)Fast and bidirectional translational research(bench-to-bedside and bedside-to-bench)performed by basic researchers and clinical investigators,preferably working alongside each other at the same institution,will be implemented;4)Close collaborations between academia,industry,regulatory bodies,and funding agencies will be established.5)There will be an investment in the other branch of CGM,personalized preventive medicine,based on the individual's genetic predisposition to cancer.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies

    Jiawen ZhangSihui YuQiao PengPing Wang...
    45-64页
    查看更多>>摘要：The intricate interplay between the human immune system and cancer development underscores the central role of immunotherapy in cancer treatment.Within this landscape,the innate immune system,a critical sentinel protecting against tumor incursion,is a key player.The cyclic GMP-AMP synthase(cGAS)and stimulator of interferon genes(STING)pathway has been found to be a linchpin of innate immunity:activation of this signaling pathway orchestrates the production of type Ⅰ interferon(IFN-α/β),thus fostering the maturation,differentiation,and mobilization of immune effectors in the tumor microenvironment.Furthermore,STING activation facilitates the release and presentation of tumor antigens,and therefore is an attractive target for cancer immunotherapy.Current strategies to activate the STING pathway,including use of pharmacological agonists,have made substantial advancements,particularly when combined with immune checkpoint inhibitors.These approaches have shown promise in preclinical and clinical settings,by enhancing patient survival rates.This review describes the evolving understanding of the cGAS-STING pathway's involvement in tumor biology and therapy.Moreover,this review explores classical and non-classical STING agonists,providing insights into their mechanisms of action and potential for optimizing immunotherapy strategies.Despite challenges and complexities,the cGAS-STING pathway,a promising avenue for enhancing cancer treatment efficacy,has the potential to revolutionize patient outcomes.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    The role of intestinal flora on tumorigenesis,progression,and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer

    Sen WangBenling XuYangyang ZhangGuangyu Chen...
    65-82页
    查看更多>>摘要：Intestinal flora affects the maturation of the host immune system,serves as a biomarker and efficacy predictor in the immunotherapy of several cancers,and has an important role in the development of colorectal cancer(CRC).Anti-PD-1/PD-L1 antibodies have shown satisfactory results in MSI-H/dMMR CRC but performed poorly in patients with MSS/pMMR CRC.In recent years an increasing number of studies have shown that intestinal flora has an important impact on anti-PD-1/PD-L1 antibody efficacy in CRC patients.Preclinical and clinical evidence have suggested that anti-PD-1/PD-L1 antibody efficacy can be improved by altering the composition of the intestinal flora in CRC.Herein,we summarize the studies related to the influence of intestinal flora on anti-PD-1/PD-L1 antibody efficacy in CRC and discuss the potential underlying mechanism(s).We have focused on the impact of the intestinal flora on the efficacy and safety of anti-PD-1/PD-L1 antibodies in CRC and how to better utilize the intestinal flora as an adjuvant to improve the efficacy of anti-PD-1/PD-L1 antibodies.In addition,we have provided a basis for the potential of the intestinal flora as a new treatment modality and indicator for determining patient prognosis.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer

    Yumei WangHaiyan WangWei ShaoYuhui Chen...
    83-103页
    查看更多>>摘要：Objective:Epigenetic abnormalities have a critical role in breast cancer by regulating gene expression;however,the intricate interrelationships and key roles of approximately 400 epigenetic regulators in breast cancer remain elusive.It is important to decipher the comprehensive epigenetic regulatory network in breast cancer cells to identify master epigenetic regulators and potential therapeutic targets.Methods:We employed high-throughput sequencing-based high-throughput screening(HTS2)to effectively detect changes in the expression of 2,986 genes following the knockdown of 400 epigenetic regulators.Then,bioinformatics analysis tools were used for the resulting gene expression signatures to investigate the epigenetic regulations in breast cancer.Results:Utilizing these gene expression signatures,we classified the epigenetic regulators into five distinct clusters,each characterized by specific functions.We discovered functional similarities between BAZ2B and SETMAR,as well as CLOCK and CBX3.Moreover,we observed that CLOCK functions in a manner opposite to that of HDAC8 in downstream gene regulation.Notably,we constructed an epigenetic regulatory network based on the gene expression signatures,which revealed 8 distinct modules and identified 10 master epigenetic regulators in breast cancer.Conclusions:Our work deciphered the extensive regulation among hundreds of epigenetic regulators.The identification of 10 master epigenetic regulators offers promising therapeutic targets for breast cancer treatment.
      原文链接:
    • NETL
    • NSTL
    • 万方数据